Skip to main content
Equibles
ERNA logo

ERNA · Ernexa Therapeutics Inc. · Metrics

Track ERNA — free

Use ERNA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ERNA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.17 +0.15 (+3.61%) At close · Sep 11
Rebalance outlook locked
Going-concern doubt — cleared Aug 6, 2026

The latest filing states the doubt was alleviated.

“As of June 30, 2026, the Company had approximately $5.0 million in cash, which is less than that needed to effect its current operating plan and forecasted cash requirements for the next twelve months. However, management expects that its ability to access capital under its ATM will cover shortfalls in its cash resources over the next twelve months from the issuance date of these financial statements.”
View the 10-Q filed Aug 6, 2026
Market Cap
$6.80M
Shares
1.63M

ERNA metrics

52 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.17
Market cap
$6.80M

Price action

20 metrics
Price change (1W)
-3.2%
Price change (30D)
-3.0%
Price change (3M)
-32.2%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
200.6%
Annualized volatility (3M)
111.7%
Beta
—
RSI (14D)
43.3
Price vs SMA 50
-11.6%
Price vs SMA 200
—
Avg volume (3M)
468,787
Relative volume
0.0
Average dollar volume
$3.08M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.63M

Valuation

12 metrics
P / E (TTM)
0.6
Trailing earnings · reciprocal yield 158.3%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
11.7×
reciprocal yield 8.6%
P / book
2.1
reciprocal yield 47.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-180.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
51.9×
reciprocal yield 1.9%
EV / revenue historical average (5Y)
51.9×
reciprocal yield 1.9%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2020-08-07

Profitability

9 metrics
Gross margin
83.5%
Operating margin
-2,693.1%
Trailing 12 months
Net margin
-7,652.7%
Gross profit (TTM)
$486,000
Operating profit (TTM)
−$13.78M
Net income (TTM)
−$12.26M
Trailing 12 months
Diluted EPS (TTM)
$6.60
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$191.16

Growth

11 metrics
Revenue growth YoY
+755.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$582,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+471.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
-50.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-383.1%
Return on assets
-194.1%
Debt / equity
—
Current ratio
2.0
EBITDA (TTM)
−$13.73M
Free cash flow (TTM)
—
Quick ratio
2.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$5.03M
Total assets
$6.32M
Total debt
$2.03M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$8.84M
Capital expenditures (TTM)
—
R&D (TTM)
$6.42M
SG&A (TTM)
$8.09M
Stock compensation (TTM)
$1.25M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
17
13F filer change QoQ
-6
Institutional ownership
176.0%

Short interest

3 metrics
Short interest
1.2%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
37 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 748592 CUSIP 114082407 13F (30d) 1 filings 1 filers Visit website Investor relations